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Abstract
Objectives: Recent developments of new direct oral anticoagulants that target specific clotting factors necessitate 
understanding of coagulation biology. The objective of this tutorial is to offer dental �rofessionals a review of 
coagulation mechanisms and the �harmacodynamics of the conventional and new oral anticoagulants. Also, we 
summarized the dental im�lications of the conventional and new anticoagulants. 
Method: We searched Medline using search terms “antithrombotic”, “antihemostasis” or “anticoagulation” and 
combined them with the search results of “dental”, “oral surgery” or “�eriodontal”. We restricted the results to 
“human” and “English”. 
Results: The early coagulation cascade, the new cell-based coagulation model, the �harmacokinetics and �harma-
codynamics of conventional antithrombotics, and new oral anticoagulants were reviewed. The new direct factor 
Xa inhibitors and the direct thrombin inhibitor (s), called direct oral anticoagulants (DOAs) have ra�id onset of 
action, fast elimination on cessation, and fewer drug-drug or drug-food interactions than warfarin. However, the 
lack of antidotes raises concerns that some dental �rocedures may trigger serious hemorrhagic events. Addition-
ally, careful �erio�erative withdrawal and resum�tion �rotocols for the DOAs are reviewed, because DOAs’ blood 
levels are de�endent on renal function. Also, various reversal strategies in the event of excessive bleedings are 
summarized. Perio�erative management of dental �atients taking new DOAs and conventional oral anticoagulants 
are also discussed. However, the �erio�erative strategies for DOAs are yet to be validated in randomized trials. 
Key Words: Coagulation cascade, cell-based coagulation model, factor Xa inhibitors, direct thrombin inhibitors, 
prothrombin complex concentrates.
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Introduction
The increasing elderly �o�ulation and long life-ex-
�ectancy lead to a high �revalence of chronic illnesses 
including heart disease and stroke. (1) These diseases 
often require antithrombotic thera�y to �revent throm-
boembolic (TE) events. The indications for antithrom-
botic thera�y are to �revent TE events and stroke in: 
(I) Atrial fibrillation and other cardiac arrhythmias; 
(II) Venous thromboembolism (dee� vein thrombosis, 
�ulmonary embolism); (III) Acute coronary syndrome 
and myocardial infarction; (IV) Pulmonary hy�erten-
sion; and (V) Cardiac valve disease and �rosthetic valve 
re�lacement. (2,3)  
Oral antithrombotic drugs can be divided into two cat-
egories: anti-�latelets and anticoagulants. Table 1 sum-
marizes these categories. Acetylsalicylic acid (as�irin) 
is the most widely used anti�latelet agent and the most 
commonly �rescribed oral anticoagulant has been war-
farin. Consequently, instructional articles automatically 
refer to oral anticoagulants as warfarin and its deriva-
tives. (2,4-7) However, the coagulation conce�t has 
been modified into a new, cell-based hemostasis model 
and several new oral anticoagulants targeting specific 
clotting factors have been introduced in 2010 – 2011. 
Only recently, two cursory reviews on these new direct 
oral anticoagulants (DOAs) have a��eared in the dental 
literature (8,9). The objectives of the �resent review are 
(1) to educate general dental �rofessionals about coagu-
lation cascade and the �harmacology of new and old 
anticoagulants and (2) to suggest �eri-surgical manage-
Antithrombotic drug 
categories 
Generic names and subgroups Comments 
Anti�latelet agents ? COX-1 inhibitor: As�irin 
? ADP receptor inhibitor:
Clo�idogrel, Prasugrel, Ticagrelor 
? Gp IIb/IIIa  inhibitor: 
Abciximab, E�tifibatide, 
Triofiban 
? Phosphodiesterase inhibitor : 
Di�yridamole ? Not licensed as a 
monothera�y for stroke 
�revention. 1
?  Bleeding time is extended without 
clinical consequences. 
? Gp IIb/IIIa  inhibitor: Intra-venous use 
only. 
? Co-administration with NSAIDs increase 
bleeding. 
? Possible rebound effects on cessation. 
? Di�yridamole is used in combination of 
as�irin,
? Di�yridamole is indicated only when 
other anti�latelets are not suitable. 
Vitamin K antagonists (VKA) 
(inhibit factors II, VII, IX, X) 
Warfarin, Coumarin, Dicoumarol, 
Phen�rocoumon, Acenocoumarol. 
? VKA may be continued with local 
hemostasis measures. 
? VKA may be withdrawn for 2-3 days �re-
o�.
? Consult with the �rescriber of VKA. 
? Interactions with many drugs and foods 
? Possible rebound effects on cessation 
Factor Xa inhibitors ? He�arin grou�: not reviewed 
(subcutaneous use only) 
? rivaroxaban  
? He�arin induced thrombocyto�enia. 
? No antidote for rivaroxaban 
Direct thrombin inhibitor  ? dabigatran ?  No antidote. 
Contraindications: 
?  Age > 75 
?  Renal dysfunction 
?  Bleeding tendency 
~260 hemorrhagic deaths in 3 years �er 
�ost-marketing surveillance by the 
manufacturer, Boehringer Ingelheim.  
Thrombolytic drugs ? tissue �lasminogen activator 
(tPA)
1. Alte�lase (tPA) 
2. Tenecte�lase( tPA) 
3. Rete�lase (tPA) 
? Stre�tokinase (Kabikinase, 
Stre�tase) 
? Urokinase (Abbokinase) 
These agents will NOT be discussed in the 
�resent review.  
? Short term use 
? Via Parenteral route 
Table 1. Antithrombotic drugs categorized by �harmacodynamics.
Reference for Table 1:
1  De Schryver, E. L., Algra, A. & van Gijn, J. (2007) Di�yridamole for �reventing stroke and other vascular events in 
�atients with vascular disease. Cochrane Database Syst Rev, CD001820. doi:10.1002/14651858.CD001820.�ub3 [doi].
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ment strategies for �atients taking new DOAs. Concur-
rently, we call for more research action utilizing these 
new DOAs in dental setting.
To conduct this review, we searched PubMed with search 
terms “anti-�latelet”, “antithrombotic”,  “anticoagula-
tion”, or “anti-hemostasis”, �ublished between 1966- 
2012 and in a se�arate search, we used the search terms 
“dental” “oral surgery” or “�eriodontal” and merged two 
searches. We collected 113 dentistry-related references. 
In the first section of this review, we reviewed the early 
coagulation cascade; in the second section, we intro-
duced the new coagulation model; in the third section, 
we �resented the new direct oral anticoagulants; and in 
the fourth section, we discussed �erio�erative manage-
ment strategy. 
Concepts on early coagulation cascade
Hemostasis involves a multi�art �hysiological �rocess 
that limits blood loss at the site of an injury while main-
taining normal blood flow elsewhere in the circulation. 
An early model of coagulation derived from in vitro 
ex�eriments and �resented in the mid-1960s (10,11) 
involved a series of biological ste�s via intrinsic and 
extrinsic �athways leading to a common �athway to 
activate factor X (f.X). The intrinsic �athway includes 
factors XII (f.XII), XI (f.XI), IX (f. IX) and VIII (f.VIII) 
as well as �rekallikrein and kininogen. The extrinsic 
�athway is com�osed of factor VII (f.VII) and tissue 
factor (TF). 
In the intrinsic �athway, activated f.XII leads to activat-
ed f. IX (f. IXa) after several ste�s of molecular activa-
tion. In turn, f. IXa converts f.X to activated f.X (f.Xa). 
On a collateral, extrinsic �athway, f.X can be activated 
by f.VII and tissue factor (TF/f.VII com�lex). Thus, f.Xa 
from both �athways converges in a common �athway 
whose constituents are factors V (f.V), �rothrombin 
(f.II), fibrinogen (f.I) and thrombin. 
Either way, activated f.X (f.Xa) is the key �layer in con-
verting �rothrombin (f.II) to thrombin, which converts 
fibrinogen (f.I) to fibrin. The activated partial throm-
bo�lastin time (aPTT) is a laboratory test for intrinsic 
�athway function and �rothrombin time (PT) test as-
sesses the function of the extrinsic �athway. (12) Each 
clotting factor leads to the activation of another, leading 
to a sufficient thrombin generation necessary for the for-
mation of fibrin. This sequence of events is summarized 
in figure 1. Within this cascade model, the involvement 
Extrinsic pathway Intrinsic pathway 
Common pathway 
XII, HMK, PK 
XI         XIa 
IX          IXa 
PL, VIIIa, Ca++
Xa
TF/VIIa 
Fibrinogen (I)                   Fibrin  
PL, Va, Ca++
PL, Ca++
Prothrombin (II)            Thrombin  
XX
Adapted from “Hoffman M, Monroe DM, 3rd (2001). A cell-based model of 
hemostasis. Thromb Haemost 85(6):958-65” 
Fig. 1. Early coagulation cascade.
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of intrinsic and extrinsic �athways is considered inde-
�endent. (13) 
While this conce�t was a huge achievement in the un-
derstanding of molecular interactions regulating co-
agulation, it had several limitations in ex�laining the 
hemostatic �rocess in vivo. Thus, several new theories 
were �ro�osed: one that extrinsic and intrinsic �ath-
ways are actually working inter-de�endently has been 
well-received. (12)  An exam�le of this collaboration of 
two �athways is that the f.VIIa/TF com�lex from the 
extrinsic �athway can activate f.IX in the intrinsic �ath-
way as well as f.X in the common �athway. (14) These 
conce�ts generated a new �aradigm advocating that 
cellular com�onents are the key �layers in coagulation 
which is controlled by the ex�ression of a variety of cell 
features and �rotein rece�tors that localize the com�o-
nents of coagulation on specific cell surfaces. Thus, a 
conce�t of coagulation evolved from a mechanism be-
ing controlled by kinetics of various �roteins to a new 
conce�t of cellular com�onents controlling the coagula-
tion �rocess. (12) We now review the new, cell-based 
coagulation model.
Concepts on the new, cell-based coagulation 
model
The new model of coagulation is a well-coordinated se-
ries of cell activation, culminating in a blood clot. (12) 
Three stages �ro�osed in this new coagulation models 
are initiation, amplification (priming) and propagation. 
In the initiation stage, TF from fibroblasts (or other TF 
bearing cells such as monocytes or endothelial cells) 
binds the activated factor VII, (a circulating coagula-
tion factor) and forms the TF/VIIa com�lex.  TF/VIIa 
com�lex in turn activates factors IX and X. The acti-
vated factor X (Xa) forms a Xa / Va com�lex on the 
surface of fibroblasts and generates a sufficient amount 
of thrombin to induce �latelet activation. (15) Thus, co-
agulation now moves to a more efficient site, the nega-
tively charged, �latelet surface. 
In the second stage, the amplification (or priming) 
�hase, the coagulation now has moved from tissue fac-
tor bearing fibroblasts to platelets that are much better 
suited for the coagulation with their negatively charged 
surfaces. Platelets adhere and accumulate cofactors on 
their surface and am�lify the coagulation. Platelets and 
coagulation factors are activated by thrombin, which in 
turn binds and cleaves �latelet �rotease-activated re-
ce�tors (PAR1 and PAR4), triggering a com�lex sign-
aling cascade. Furthermore, thrombin activates factors 
V, VIII, and XI also. (15) This is a crucial �oint many 
health care �rofessionals are concerned about, because 
multifaceted anticoagulation ability will com�licate the 
reversal �rocess if excessive hemorrhage occurs. (16) 
In the final propagation phase, the tenase (factor “ten” 
activator) and �rothrombinase (f.Xa / f.Va) com�lexes 
are assembled on the �latelet surface, and large-scale 
thrombin generation takes �lace. (12) Tenase can origi-
nate from either the extrinsic �athway or from the in-
trinsic �athway. Intrinsic tenase is made of f.IXa and f. 
VIIIa with Ca++  and  extrinsic tenase consists of TF/f.
VIIa with Ca++. Intrinsic tenase is 50 times more effi-
cient than extrinsic tenase in f.Xa ex�ression. Addition-
ally, �rothrombinase com�lex (f.Xa / f.Va) is �rotected 
from tissue factor inhibitors, for it does not contain TF 
and thus a �owerful �roduction of f.Xa and thrombin 
formation results. This leads to a large scale fibrin for-
mation. (15)  These �rogressive �hases are summarized 
in figure 2.
Under normal conditions, tissue factors do not come 
into contact with circulating vascular clotting fac-
tors. However, in some instances such as �ercutane-
ous coronary intervention, hemodialysis, or cardiac 
valve re�lacement surgery, these two com�onents come 
into contact resulting in a clot and subsequent adverse 
outcomes, such as myocardial infarction or stroke. In 
various inflammatory states, TF expression can also be 
u�-regulated in monocytes and endothelial cells by bac-
terial antigens, inflammatory cytokines, (17) or tumor 
necrosis factor. (18) This ex�lains the hy�er-coagulat-
ive state accom�anying infection. Now that we have 
reviewed both old and new coagulation models, it will 
be easier to understand where the new antithrombotic 
drugs inhibit the coagulation mechanism.  
New antithrombotic agents 
3-1. New anti�latelet drugs 
Platelets �lay a central role in thromboembolic (TE) 
events and four �otential rece�tors have been recog-
nized in �latelet activation. (19) 
The first pathway via the thromboxane A2 synthesis is 
through which the conventional anti�latelet agent, as-
�irin, exerts its anti�latelet action. As�irin is a cyclo-
oxygenase (COX)-1 inhibitor that irreversibly inhibits 
platelet activation. It is an efficient and inexpensive 
drug but cause mucosal irritation and may cause inter-
nal bleeding. Thus, in recent years, a grou� of new an-
ti�latelet agents has been develo�ed. 
The second �athway includes thieno�yridines that in-
clude clo�idogrel (Plavix®), and prasugrel (Effient®) that 
irreversibly block adenosine di�hos�hate (ADP) activa-
tion of �latelets through the ADP rece�tor P2Y12. (20) 
A non-thieno�yridine P2Y12 rece�tor inhibitor, ticagre-
lor (Ticlid®) is a reversible anti-�latelet agent much more 
�otent and has faster onset of action than clo�idogrel. 
However, it accom�anies more adverse effects such as 
dys�nea, hematoma and excessive bleeding. (21) The 
third �athway is via von Willebrand factor (vWF) and 
�latelets’ glyco�rotein (G�)-Ib rece�tor. When ru�ture 
of an atherosclerotic �laque ex�oses collagen and vWF, 
the A1 domain of vWF binds to the G�-Ib rece�tor of 
Med Oral Patol Oral Cir Bucal. 2013 May 1;18 (3):e461-72.                                                                                                                                                                      Anticoagulation and dentistry
e465
�latelet. The fourth �athway for �latelet activation is via 
�rotease activator rece�tor-1 (PAR-1). If �latelet acti-
vation is blocked through any one of these �athways, 
�latelet membrane glyco�rotein IIa/IIIb cannot bind to 
fibrinogen and unable to generate a hemostatic plug. 
(22) These four �athways through which �latelet aggre-
gation can be inhibited are illustrated in figure 3.
3-2. New direct oral anticoagulants (DOAs)
The conventional vitamin K antagonist (VKA), war-
farin, has several drawbacks that limit its clinical util-
?
?
?
?
TF
VIIa
TF-Bearing cell 
IX
IXa 
X
Xa/ Va 
Xa 
V
Va
Thrombin
Activated Platelet 
VVa
VIIIa IXa 
vWF/VIII 
?
???????
????????Activated platelet 
VIIIa/IXa  
(Intrinsic tenase) 
Va
Va/Xa
(Prothrombinase) 
X
TF-Bearing cell 
VII
TF/VIIa
Thrombin 
Prothrombin (II) 
?
Xa 
IX
Prothrombin (II) 
FibrinFibrinogen (I) 
Propagation
Amplification 
Initiation 
Adapted from  
1. “Hoffman M, Monroe DM, 3rd (2001). A cell-based model of hemostasis. Thromb Haemost 85(6):958-65”  
2. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 
2006:26(1):41-8. 
Fig. 2. New cell-based coagulation model.
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ity: numerous drug-drug and drug-food interactions, 
the genetic differences in VKA metabolism via cyto-
chrome P450, and wide inter-individual differences in 
�harmacokinetics as well as the narrow thera�eutic 
window which requires frequent testing. Therefore, �a-
tients’ compliance directly affects its clinical efficacy. 
Warfarin stays in the thera�eutic range a��roximately 
60% of the time, with an average of ~12% of the time in 
the su�ra- and ~20% of the time in the sub-thera�eutic 
range. (23) For these reasons, the im�etus for develo�-
ment of safer anticoagulants has been active resulting 
in several new direct oral anticoagulants (DOAs). These 
are direct factor Xa inhibitors rivaroxaban (Xarelto®), 
a�ixaban (Eliquis®), edoxaban and direct thrombin in-
hibitor dabigatran (Pradaxa®). (Tables 2,3) summarizes 
the �harmacokinetics �harmacodynamics, including 
dietary �otentiators or inhibitors of new DOAs as well 
as warfarin.
New DOAs have ra�id onset of action, fast elimination 
on cessation and have fewer drug-drug or drug-food in-
teractions. This obviates the need for frequent testing as 
with warfarin. However, no reversal agents are available 
at �resent and minimal trauma such as subgingival �eri-
odontal scaling, gingivectomy, or sim�le exodontia have 
�otential to become serious hemorrhagic events. We will 
discuss the new direct oral anticoagulants in detail. 
3-2-a.  Direct factor Xa inhibitors (Xaban)
Rivaroxaban is one of the direct factor Xa (f.Xa) inhibi-
tors a��roved by FDA for the �revention of thromboem-
bolic (TE) events in patients with atrial fibrillation.(24) 
The other drug in this grou� is a�ixaban for which FDA 
just a��roved its use in Jan. 2013. These drugs inhibit 
both free f.Xa and bound f.Xa within the �rothrombi-
nase com�lex. Rivaroxaban reaches its �eak �lasma lev-
el at ~3 hours after administration and ~65% is excreted 
via urine and ~35% via biliary and fecal routes. There-
fore, in the elderly or in �ersons with renal im�airment, 
rivaroxaban would have a �rolonged half-life. 
3-2-b. Direct thrombin inhibitor (DTI)
Dabigatran is one of the direct thrombin inhibitors (cf. 
?
?
?
?
?
P2Y12
TXA2
GP-Ib 
?ADP
vWF
Thrombin
TR
Ticlopidin
Clopidogrel
Prasugrel 
Ticagrelor
Cangrelor
Elinogrel
PAR-1 
Platelet
Terutroban 
Aspirin 
ARC1779 
ALX-0081 
AJW200
(Drugs in 
development)
SCH530348 
SCH205831 
SCH602539 
E5555
(Drugs in 
Development)
Legend
TR = Thromboxane receptor
PAR = Protease-activated receptor 
GP- Ib =Platelet glycoprotein-Ib receptor 
TXA2 =Thromboxane A2  
ADP = Adenosine diphosphate,  
vWF = von Willebrand Factor 
Adapted from “Siller-Matula JM, Krumphuber J, Jilma B (2010). 
Pharmacokinetic, pharmacodynamic and clinical profile of novel 
antiplatelet drugs targeting vascular diseases. Br J Pharmacol 
159(3):502-17.” 
Fig. 3. Pathways of anti�latelet mode of action.
Med Oral Patol Oral Cir Bucal. 2013 May 1;18 (3):e461-72.                                                                                                                                                                      Anticoagulation and dentistry
e467
 Vitamin K 
Antagonist
Direct Xa 
inhibitors 
Direct thrombin 
inhibitors 
Cox-1 inhibitors P2Y12 ADP 
rece�tor 
inhibitors 
Drug names Warfarin Rivaroxaban,  
a�ixaban  
Diabigatran3  As�irin3 Clo�idogrel,4
Ticlo�idine, 
Prasugrel 
Peak of action 
(tmax)
4-5 days 1-3 hrs. 1-3 hrs. 0.5 – 4 hrs. 3 to 7 days for 
Clo�. 1-3 hrs. 
for others 
Elimination 
half-life (t1/2)
36-42 hrs. 9-15 hrs. 14-17 hrs.3 15-30 min 24 to 36 hrs for 
Ticlid, 7-8 hrs 
for others. 
Metabolized 
via CYP? 
Yes  Yes (CYP3A4, 
CYP2J2 and more) 
Minor Minor Yes (CYP2C19 
and CYP3A4 
and more) 
Route of 
elimination 
Renal and bile 65% renal   
35% fecal 
80% renal  
20% fecal 
Mostly renal 54% renal 
46% fecal 
Interaction 
with other 
drugs and 
food
Genetics*
Potentiators1
Ci�rofloxacin;     
Cotrimoxazole; 
Erythromycin; 
Azithromycin; 
Fluconazole; 
Isoniazid; 
Metronidazole;
Amiodarone;
Clofibrate; 
Diltiazem; 
Fenofibrate; 
Pro�afenone;
Pro�ranolol;
Phenybutazone; 
Piroxicam;
Cimetidine; 
Ome�razole; 
Fish oil; 
Mango.
Inhibitors
Griseofulvin; 
Nafcillin; 
Ribavirin; 
Rifam�in; 
Barbiturates; 
Carbamaze�ine; 
Cholestyramine; 
Foods with high 
Vitamin K, such 
as Avocado, Kale. 
Potentiators2
Itraconazole;  
Voriconazole;  
Posaconazole; 
Ritonavir; 
Clarithromycin; 
Na�roxen;
Anticoagulants. 
Inhibitors 
Rifam�icin; 
St. John Wort; 
Phenytoin; 
Carbamaze�ine ; 
Phenobarbital.
Potentiators2
Amiodarone;
Vera�amil;  
Quinidine; 
Digoxin;
Ketoconazole; 
Clarithromycin; 
As�irin;
Clo�idrogrel;
Diclofenac; 
Inhibitors 
Antacids; 
Panto�razole; 
Rifam�in; 
St. John Wort. 
Potentiators 
Other
Anticoagulants; 
SSRIs; 
Alcohols;
Enala�ril; 
Inhibitors3
Indomethacin; 
ibu�rofen;
na�roxen.
Potentiators4
Phenytoin; 
Tamoxifen;
Tolbutamide; 
Fluvastatin; 
Other
anticoagulants. 
Inhibitors:  
Ome�razole; 
Table 2.  Pharmacokinetics of warfarin and new direct oral anticoagulants.
• CYP: cytochrome P-450.
• *CYP2C9*3 allele may be associated with retarded elimination of (S)-warfarin and may increase the clinical effects.
• Interaction is a partial list of only highly probable interaction. Many probable, possible interactions are reported. In reference †
• SSRIs: selective serotonin reuptake inhibitors
References for Table 2:
1 Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., Palareti, G. & American College of Chest, P. (2008) Pharmacology and 
management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th 
Edition). Chest 133, 160S-198SVKA
2 Nutescu, E., Chuatrisorn, I. & Hellenbart, E. (2011) Drug and dietary interactions of warfarin and novel oral anticoagulants: an 
u�date. J Thromb Thrombolysis 31, 326-343
3 Hohlfeld, T., Zimmermann, N., Weber, A. A., Jessen, G., Weber, H., Schror, K., Holtje, H. D. & Ebel, R. (2008) Pyrazolinone analge-
sics �revent the anti�latelet effect of as�irin and �reserve human �latelet thromboxane synthesis. J Thromb Haemost 6, 166-173.
4 Mackenzie, I. S., Coughtrie, M. W., MacDonald, T. M. & Wei, L. (2010) Anti�latelet drug interactions. J Intern Med 268, 516-529.
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to Figs. 1,2) a��roved by FDA for stroke �revention in 
non-valvular atrial fibrillation (A-fib). (25) It has a half-
life of 14 -17 hours and 80% is excreted through urine 
and 20% through the fecal route. Therefore, in �ersons 
with im�aired renal function, the half-life will increase 
and invasive �rocedures that require cessation of da-
bigatran should be determined according to renal func-
tion. (26) Although reliable �harmacodynamics and 
�harmacokinetics eliminate frequent testing and ecarin 
clotting time (ECT) and thrombin clotting time (TT) as-
says may assess antithrombotic action of new DOAs, 
there is no de�endable way of determining thera�eutic 
�lasma levels of dabigatran. (27) Neither aPTT, PT nor 
INR is sufficiently precise to measure the clinically ef-
fective serum level of DOAs. (28) 
Not as extensive as warfarin, some drug-drug interac-
tions have been demonstrated with dabigatran: with 
quinidine, ketoconazole, amiodarone, and vera�amil 
that can increase the dabigatran �lasma concentrations. 
(26) Co-administration of other anticoagulants or non-
steroidal anti-inflammatory drugs will also increase 
dabigatran level. On the other hand, rifam�icin and 
some �roton �um� inhibitors such as ome�razole will 
decrease dabigatran levels. 
Clinical implications of the new anticoagulants  
Currently, there is no �ublished research evidence uti-
lizing new DOAs in the dental setting. However, we 
summarized �erio�erative strategies that a��eared in 
medical journals so that dental �rofessionals will have 
adequate basic knowledge when they consult �hysicians 
regarding their �atients on new DOAs. In addition, ac-
tive research in the develo�ment of the antidotes for new 
DOAs makes it im�erative for dental �rofessionals to 
have a clear understanding of coagulation mechanisms. 
4-1. General dental considerations
Scheduling early in the week and early morning of the 
day a��ointment may be necessary to afford additional 
visit in case of excessive bleeding. Furthermore, addi-
tional su��lies to deal with the �ost-surgical bleeding 
should be considered for �atients taking anticoagulants. 
(4,29,30) Some suggested additional su��lies are ab-
sorbable hemostatic dressings such as oxidised cellu-
lose (Surgicel®), collagen s�onge (Haemocollagen®) or 
resorbable gelatin s�onge (S�ongostan®), along with re-
sorbable and non- resorbable sutures. Also suturing the 
extraction sites and �ressure a��lication with gauzes 
saturated with tranexamic acid has also been suggested 
to �revent �ost-surgical bleeding. (31) 
Careful �re-o�erative assessment of �atients’ medi-
cal profile was a common recommendations and some 
suggested routine laboratory studies including: a com-
�lete blood count (CBC), �rothrombin time (PT), acti-
vated �artial thrombo�lastin time (aPTT), INR in case 
of VKA, and bleeding time. Arranging an after-hours 
res�onse team should be considered for those general 
dental �ractitioners (GDPs) without hos�ital �rivileges 
to counter �ost-o�erative bleeding.  Most bleeding risk 
studies com�ared those who sto��ed warfarin to those 
who stayed on warfarin during the dental �rocedures 
and found that bleeding was not significantly different. 
However, if the bleeding incidence was com�ared to the 
controls not taking warfarin, the indirectly calculated 
relative bleeding risk was about a 10-fold increase in 
those who are on warfarin (9-10%) than those who do 
not take anticoagulants (1%). (32) In addition, some 
delayed bleedings were re�orted after 24 or 48 hours.
(33) Therefore, �ost-surgical bleeding in �atients taking 
Abbreviation Definition 
aPPT activated Partial Thrombo�lastin Time 
ADP Adenosine Di�hos�hate 
ATIII Antithrombin III 
CBC Com�lete Blood Count
COX cyclooxygenase 
DTI Direct Thrombin Inhibitor 
Extrinsic tenase tissue factor + f.VIIa + Ca++
f.V or V Factor V 
f.VII or VII Factor VII 
f.VIII or VIII Factor VIII 
f.IX or IX Factor IX 
f.X or X Factor X 
f.XI or XI Factor XI 
f.XII or XII Factor XII 
f.Va or Va activated Factor V 
f.VIIa or VIIa activated Factor VII 
f.VIIIa or VIIIa activated Factor VIII 
f.IXa or IXa activated Factor IX 
f.Xa or Xa activated Factor X 
f.XIa or XIa activated Factor XI 
Fibrinogen Factor I 
Fibrin Factor Ia 
FDA Food and Drug Administration 
HIT He�arin Induced Thrombocyto�enia 
HMK High Molecular weight Kininogen 
INR International Normalized Ratio 
Intrinsic tenase f. IXa + f. VIIIa + Ca++
LMWH Low Molecular Weight He�arin 
OA Oral Anticoagulant 
PAR Protease-Activated Rece�tors 
PF4 Platelet Factor 4 
PK Prekallikrein 
Prothrombin Factor II 
Prothrombinase f.Xa  + f.Va + Ca++
PT Prothrombin Time 
PTT Partial Thrombo�lastin time 
T Thrombin 
Thrombin f.IIa (activated Factor II) 
TF Tissue Factor 
TFPI Tissue factor �athway inhibitor 
UFH Unfractioned He�arin 
vWF von Willebrand factor 
Table 3. Table of abbreviations.
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anticoagulants is much greater than what is ex�ected in 
the general dentist’s office (GDPs) and setting up an ef-
fective �ost-surgical res�onse �lan will be necessary. 
As to the risk factors for �ost-dental surgical bleeding, 
we �ostulated that (a) the severity of systemic morbidity 
requiring a high degree of anticoagulation, (b) co-mor-
bidity such as renal insufficiency and hepatic dysfunc-
tion, and (c) the surgical trauma involved in dental �ro-
cedures may all influence the bleeding risk. However, 
there is no clear definition of significant bleeding in the 
dental setting or clear guidelines for dental �rocedures 
with high bleeding risk. We reviewed the definition of 
significant bleeding by several authors and found Lock-
hart and colleague’s definition is the most reasonable. 
(34) They defined significant bleeding as: 
1) Continues beyond 12 hours; (However,) in our o�in-
ion, even bleeding that continues to 5-6 hours should be 
considered significant. 
2) Causes the �atient to call, return to the dental �racti-
tioner, or visit the emergency de�artment;
3) Results in the develo�ment of a large hematoma or 
ecchymosis within the oral or adjacent soft tissues;
4) Requires a blood transfusion or other blood �roducts.
As for the determination of invasiveness of dental �ro-
cedures, Muthukrishnan et al. surveyed general dental 
�ractitioners (GDPs) and found that 71% of the GDPs 
surveyed considered subgingival debridement as a high 
bleeding risk, 48% inferior alveolar block, and 32% 
subgingival restoration as high bleeding risks. (35) For 
exodontia, single and u� to 3 extractions were consid-
ered a minor bleeding risk. 
4-2. Managing �atients on anticoagulants in dental-
surgical setting
Recent American College of Chest Physicians’ (ACCP) 
Evidence-Based Clinical Practice Guidelines reflects 
the controversy surrounding the withdrawal/continu-
ation of vitamin K antagonists (VKAs)  and modified 
the �ast recommendation: In dental �rocedures with 
low bleeding risk, VKAs may be continued with im-
�lementation of local haemostatic measures or may be 
interru�ted for 2-3 days �rior to surgery. (28) However, 
most dental �rofessionals favor continuing VKAs when 
International Normalized Ratio (INR) is below 3.5.  As 
Ball em�hasized (36) (1) consulting the �rescribing 
�hysician(s) to ascertain the �atient’s medical status 
that required anticoagulation thera�y, (2) checking the 
latest INR and testing it again on the day of the dental 
�rocedure may be very im�ortant in �reventing throm-
boembolic (TE) events because VKA levels fluctuate 
with diet and �atient’s com�liance.  If INR > 3.5 with 
moderate bleeding risk, withdrawal of VKA with �hy-
sician’s a��roval for 2-3 days may be necessary. Also 
hemostatic measures described in section 4-1 should be 
em�loyed. In high bleeding risk �rocedures including 
�eriodontal surgery, surgical extraction, multi�le ex-
tractions (> 3 teeth), osteo�lasty, and extensive head and 
neck surgery, a withdrawal of VKA in conjunction with 
subcutaneous or intravenous he�arin usage was recom-
mended. (36) This protocol is illustrated in figure 4. 
The withdrawal of new DOAs �rotocol is more com�lex 
than VKA because no sim�le reversal agents are avail-
able. The �rotocol is governed by the half-life of the 
drug, invasiveness of the (dental) �rocedures, the �a-
tients’ co-morbidities, and TE risks. As the elimination 
half-life of dabigatran is 12-18 hours, if the bleeding 
risk is high, the last dose should be given 3 days �rior to 
the surgery (ski� for 2 days). (28) If moderate hemosta-
sis is acce�table, the last dose should be given -2 days 
(ski��ing 1 day). In case of moderate renal im�airment, 
namely creatinine clearance is (CrCl) 30-50 mL/min, 
ski� 4 doses (ski� for 2 days) for low bleeding risk �ro-
cedures and 6-8 doses (ski� 3-4 days) for high bleeding 
risk �rocedures.(28,37) For rivaroxaban with half-life of 
~9-10 hours, the renal function is less critical in drug 
elimination. Thus, the last dose should be given on -2 
days for the low bleeding risk and on -3 days for high 
bleeding risk �rocedures res�ectively. Another factor 
that should be considered is the individual �atients TE 
risk. If TE risk is high, bridging with he�arin(s) without 
overla��ing with DOAs is suggested. The �erio�erative 
protocols for DOAs are summarized in figure 5.
For the anti�latelet agents, the �erio�erative �rotocol is 
similar to the other antithrombotics. If the bleeding risk 
of �rocedure is low, not sto��ing the anti�latelet is rec-
ommended. (37) Resum�tion of as�irin results in nearly 
immediate maximal drug effects. However clo�idogrel 
will take almost 7 days to reach the maximal effective 
level. Administering the initial loading dose may short-
en this lag �eriod (37). 
4-3. Reversal of direct oral anticoagulants 
Although new DOAs have the advantage of stable �har-
macological action and less interaction with foods or 
other drugs, the most im�ortant disadvantage of these 
new drugs is the lack of specific reversal agents. In case 
of excessive bleeding, the knowledge of reversal strat-
egy will em�ower dental �rofessionals. 
In case of warfarin-related major bleeding, vitamin K 
may be administered. However, it takes almost 24 hours 
to bring INR to normal range. Therefore, in urgent he-
morrhage caused by VKA over-dose, nonspecific pro-
hemostatic agents, such as �rothrombin com�lex con-
centrates (PCCs), are indicated. (38)
The first line of defense in any bleeding is discontinua-
tion of the causative medication and utilization of local 
measures such as �ressure with tranexamic acid-soaked 
gauzes, or other hemostatic �roducts. If DOA adminis-
tration is recent, gastric lavage or activated charcoal can 
be effective. (38)  If these measures fail, hemodialysis 
or administration of either 3-factor (II, IX, and X) or 
4-factor (II, VII, IX, and X) PCC should be considered. 
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Also in the murine model, fresh frozen �lasma (FFP) 
was able to reduce hemorrhage. However, due to the in-
convenience of thawing FFP, PCCs or recombinant fac-
tor VIIa (rFVIIa) is gaining �o�ularity over FFP. 
Ex vivo trial in humans also showed that activated four 
factor PCC reversed the effects of rivaroxaban and da-
bigatran. (39,40) In the U.S., unactivated 4- factor PCCs 
are not available but activated PCCs that contain simi-
lar concentrations of non-activated factors II, IX, and 
X and activated factor VII are available. PCC has been 
used in the dental setting successfully. (41) However, 
caution must be exercised in using PCC or rFVIIa be-
cause they carry thrombogenic risks. 
Conclusion 
Although the rate of thromboembolic events is low, (a�-
�roximately 0.5%) in the dental setting (42,43), most 
dental �rofessionals favor continuing VKAs (warfarin) 
for dental surgery because the adverse outcomes of dis-
continuation are much more serious than bleeding risks. 
However, the emergence of new direct oral anticoagu-
lants �oses some challenges due to the lack of sim�le 
reversal agent in the event of �ost-surgical bleeding. 
Future randomized trials utilizing new direct oral anti-
coagulants like the direct factor Xa inhibitors or direct 
thrombin inhibitors are warranted.  
                                                                                                        
Day - 5 Day - 4 Day - 3 Day - 2 Day - 1 Surgery Day +1 Day +2 Day +3 
Low bleeding risk (1). Continue 
VKAs and 
procedure 
High bleeding risk 
(2). Adjust dose 
and re-check INR. 
If < 3.5, proceed. 
If >3.5, reschedule.
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Fig. 4. Perio�erative management strategies for Vitamin K antagonists.
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